| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_db304b0b56a0b1201d8754af806cd838 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-70596
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-26 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6893
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6872
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-06 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-06 |
| filingDate |
2022-06-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6743bd954a34576f6edbb3ee0cca4dd0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fcafbc7bcef865092fff9c58faeb472a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6936d96bb5563223eda3b041884d8987
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_41893e2a3508500983387cd89e15c2d2 |
| publicationDate |
2022-08-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CN-114966057-A |
| titleOfInvention |
An immune marker of tuberculosis and its application |
| abstract |
The invention relates to the technical field of biomedicine, in particular to an immune marker of tuberculosis and its application. The present invention confirms through experiments that the expression of CD355 (also known as ClassI-restricted Tcell-associated molecule, referred to as CRTAM) will lead to corresponding changes in the bactericidal effect of human peripheral lymphocytes on intracellular infection of Mycobacterium tuberculosis. Animal experiments have shown that compared with wild-type mice, mice with a deletion of the CD355 gene are more susceptible to Mycobacterium tuberculosis infection, that is, CD355 is an important target for host-targeted immune adjuvant therapy for tuberculosis. This study can be used for It has a good application prospect in the preparation of related products for screening or diagnosis, efficacy evaluation, prognosis and recurrence risk assessment. |
| priorityDate |
2022-06-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |